Several quantitative structure− activity relationship (QSAR) methods were applied to 29
chemically diverse D1 dopamine antagonists. In addition to conventional 3D comparative …

This study is focused on the identification of structural features that determine the selectivity
of dopamine receptor agonists toward D1 and D2 receptors. Selective pharmacophore …

Dopamine (DA) receptors, a class of G-protein coupled receptors (GPCRs), have been
targeted for drug development for the treatment of neurological, psychiatric and ocular …

The dopamine subtype 3 receptor (D3) is a promising therapeutic target for the treatment of
cocaine addiction, schizophrenia, Parkinson's disease, and other disorders, but little is …

A series of 37 benzolactam derivatives were synthesized, and their respective affinities for
the dopamine D2 and D3 receptors evaluated. The relationships between structures and …

The dopamine D3 receptor has been recognized to play an important role in the molecular
mechanisms of various neuropsychiatric disorders. The development of new dopamine D3 …

The dopamine D3 receptor (D3R) has been implicated in substance abuse and other
neuropsychiatric disorders. The high sequence homology between the D3R and D2R …

Small molecules targeting allosteric pockets of G protein–coupled receptors (GPCRs) have
a great therapeutic potential for the treatment of neurologic and other chronic disorders …

Subtype-selective agents for the dopamine D3 receptor (D3R) have been considered as
potential medications for drug addiction and other neuropsychiatric disorders. Medicinal …

Biased agonism at GPCRs highlights the potential for the discovery and design of pathway-
selective ligands and may confer therapeutic advantages to ligands targeting the dopamine …